CAS: 14755-02-3; (E)-3-(3-Hydroxyphenyl)Acrylic Acid

相似化合物

96251-92-2 127791-54-2 501-98-4

上下游产品

CAS号57668-34-5 3-[3-(Benzyloxy... | CAS号3470-49-3 5-羟基-1-茚酮 | CAS号20375-42-2 3-乙酸基肉桂酸 | CAS号26231-89-0 3-(3-hydroxyphe... | CAS号28495-90-1 4(1H)-Pyrimidin... | CAS号331-39-5 咖啡酸 | CAS号6968-35-0 7-羟基-1-茚酮 | CAS号61389-68-2 3-(3-羟苯基)丙酸甲酯 | CAS号15854-56-5 methyl 3-(3-met... | CAS号102872-33-3 Metatyrosine

L-M-酪氨酸置于aromatic Ammonia-lyase From Loktanella Atrilutea体系中,用 Aq. Buffer 用作溶剂,化学反应生成间羟基肉桂酸
参考文献:Loktanella Atrirudea 芳香氨裂解酶的生物催化潜力
标题:Loktanella Atrirudea 芳香氨裂解酶的生物催化潜力
摘要:来自loktanella Atrirudea ( La Aal) 的芳香氨裂解酶对 3,4-二甲氧基反式肉桂酸表现出高活性,而对天然 Aal 底物的活性却出人意料地降低.在最佳反应条件下,La Aal 表现出多种肉桂酸转化的多功能性.虽然la Aal 可能被归类为酪氨酸氨裂解酶(tal,Ec 4.3.1.23),但其强烈独特的属性表明其在非天然苯丙氨酸的转化中发挥着重要作用.
Doi:10.1002/cbic.202400011

专利信息

专利号:US-2013150622-A1
优先权日:2011-12-12
标题:Stereoselective synthesis of tapentadol and its salts
发明人：FANDRICK DANIEL ROBERT; RODRIGUEZ SONIA; YANG BING-SHIOU
权利人:BOEHRINGER INGELHEIM INT; BOEHRINGER INGELHEIM INT
摘要:A process for the synthesis of a salt of tapentadol.

专利号:WO-2012089181-A1
优先权日:2010-12-30
标题 :O-substituted (2r,3r)-3-(3-hydroxyphenyl)-2-methyl-4-pentenoic acids and a method of obtaining the same
发明人：VLASAKOVA RUZENA; HAJICEK JOSEF; ZEZULA JOSEF
权利人:ZENTIVA KS; VLASAKOVA RUZENA; HAJICEK JOSEF; ZEZULA JOSEF
摘要:The compounds of general formula II are new and represent important intermediates in the synthesis of tapentadol. In the synthesis of tapentadol of formula I and its pharmaceutically acceptable salts, O-protected (2R,3R)-acids of general formula II, in step A, are reacted in an inert organic solvent with an activating agent, optionally in presence of a catalyst or a base; in step B, the obtained compounds of general formula V, wherein R has the above mentioned meaning and X stands for chlorine or alkoxycarbonyloxyl group O-CO-OR 1 or pivaloyloxyl O-CO-t-Bu group, wherein R 1 is methyl or ethyl, are reacted with dimethylamine or its salts optionally in presence of a base; in step C, the obtained N, N-dimethylamides of general formula VI, wherein R has the above mentioned meaning, are reduced by means of hydride agents in a suitable solvent; in step D, the produced alkeneamines of general formula VII, wherein R has the above mentioned meaning, are hydrogenated on a metal catalysts in a suitable solvent; and, finally, in step E, the produced alkaneamines of general formula VIII, wherein R has the above mentioned meaning, are O-dealkylated by means of dealkylating agents, and, if required, the obtained tapentadol is converted by the action of a pharmaceutically acceptable acid to respective salts, e.g. hydrochloride.

专利号:US-6180830-B1
优先权日:1995-11-08
标题 :Method for preparing a bimetallic ruthenium/tin catalyst and a process for the synthesis of aldehydes
发明人：JACQUOT ROLAND
权利人:RHODIA CHIMIE SA
摘要:The present invention relates to a new process for the preparation of a bimetallic ruthenium/tin catalyst. The process for the preparation of a bimetallic ruthenium/tin catalyst according to the invention is characterised by the fact that it consists in carrying out the reduction of a ruthenium complex having an electrovalency of -4 and a coordination number of 6, the ligands being either a halogen atom or an anion or a tin halide. The catalyst is further employed for the preparation of aldehydes by reduction, in the vapor phase, of carboxylic acids, esters and anhydrides.

专利号:US-11746364-B2
优先权日:2018-01-17
标题 :Enzymatic synthesis of kavalactones and flavokavains
发明人：PLUSKAL TOMÃ?S; Weng jing-ke
权利人:WHITEHEAD INST BIOMEDICAL RES
摘要:Disclosed are methods, compositions, proteins, nucleic acids, cells, vectors, compounds, reagents, and systems for the preparation of kavalactones, flavokavains, and kavalactone and flavokavain biosynthetic intermediates using enzymes expressed in heterologous host cells, such as microorganisms or plants, or using in vitro enzymatic reactions. This invention also provides for the expression of the enzymes by recombinant cell lines and vectors. Furthermore, the enzymes can be components of constructs such as fusion proteins. The kavalactones produced can be utilized to treat anxiety disorder, insomnia, and other psychological and neurological disorders. The flavokavains produced can be utilized to treat various cancers including colon, bladder, and breast cancers.

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人：MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.